Memphasys Secures Extended Convertible Note Terms from Major Shareholder

The latest update is out from Memphasys Ltd ( (AU:MEM) ).

Memphasys Limited has extended the maturity date of its convertible notes with major long-term shareholder Peters Investments to 30 June 2026, giving the company more time and flexibility to manage its repayment obligations while maintaining the principal and conversion terms. The board views the revised timetable for cash repayment of accrued interest and the unchanged note structure as strengthening balance sheet flexibility and signalling strong ongoing support from Peters Investments for the company’s strategic direction. The move follows recent operational progress, including CE Mark approval for its technology, multiple commercial agreements in Europe and India and the receipt of early commercial orders, with the board positioning 2026 as a year to build on 2025’s step-change in execution and advance toward sustained commercialisation.

The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.

More about Memphasys Ltd

Memphasys Limited is an Australian-based reproductive biotechnology company focused on commercialising the Felix™ System, a patented bioseparation technology that isolates the most viable sperm cells for human assisted reproduction. By combining electrophoresis with size-exclusion membranes, Felix™ offers a fast, gentle and standardised alternative to traditional centrifugation, aiming to enhance sperm quality, reduce laboratory time and establish a new global standard in sperm preparation for assisted reproductive technology procedures through a mix of direct and distribution-led sales channels.

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$13.07M

Find detailed analytics on MEM stock on TipRanks’ Stock Analysis page.